Solid Biosciences Inc. (NASDAQ: SLDB) announced an insider disposition on February 18, 2026, when Chief Operating Officer David T. Howton sold 7,469 shares of the company’s common stock for about $43,494. The reported sale occurred at prices between $5.23 and $6.14 per share, and the company’s shares were trading at $5.92 at the time of reporting. Solid Biosciences has a market capitalization of $460.45 million.
The Form 4 filing submitted to the Securities and Exchange Commission states the divestiture was completed to satisfy withholding tax obligations following the vesting of restricted stock units. The filing follows an earlier transaction by Howton on February 13, 2026, when he exercised options on 14,687 shares of Solid Biosciences common stock.
Market movement around the stock has been notable in the short term. SLDB shares declined 2.63% over the past week, a change the company’s analytical coverage describes as consistent with the stock’s recent volatility. The reported trading price of $5.92 sits slightly above InvestingPro’s Fair Value estimate.
Corporate and clinical developments accompany the insider transactions. Solid Biosciences reported that it has reached agreement with the U.S. Food and Drug Administration on the design of its Phase 3 clinical trial, IMPACT DUCHENNE, for its investigational treatment candidate SGT-003. The FDA approved the company’s proposed randomized, double-blind, placebo-controlled trial framework, which targets a defined patient population and uses change from baseline in Time to Rise velocity at 18 months as the primary endpoint.
Operational updates include dosing activity in earlier-stage studies. The company has dosed 33 participants in its Phase 1/2 INSPIRE DUCHENNE trial and describes the therapy as generally well tolerated to date. In a separate program, Solid Biosciences received Orphan Drug designation from the FDA for SGT-212, an investigational gene therapy for Friedreich’s ataxia, and has dosed the first participant in the Phase 1b FALCON trial evaluating SGT-212 in adults with Friedreich’s ataxia and cardiac hypertrophy.
Analyst coverage remains constructive ahead of the company’s next earnings release, which is scheduled for March 6. Although Solid Biosciences has not been profitable over the last twelve months, analysts continue to express a bullish consensus. Citizens has reiterated a Market Outperform rating on the stock and kept a $15.00 price target, citing the FDA alignment on the Phase 3 trial design as a supporting factor.
The Form 4 disclosure and the company’s clinical-stage milestones were filed and reported in regulatory and company communications. Investors and market participants may weigh the insider sale alongside the clinical progress and upcoming earnings date when assessing the company’s near-term outlook and stock performance.